Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study
European Archives of Oto-Rhino-Laryngology · 2025-10 · 282 (10) · 5333-5341
DOI: 10.1007/s00405-025-09602-7 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 30.07.2025. Verfasst von Xiaoqiong Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Changhai Hospital, Naval Medical University, No. 168, Changhai Road, Yangpu District, Shanghai, China. Hauptthemen laut MEDLINE: Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Standard of Care, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
PURPOSE: Improving the prognosis of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have intermediate- and high-risk factors has long been a priority for head and neck surgeons. This study aims to evaluate programmed death-1 (PD-1) inhibitors administered as maintenance monotherapy after standard of care in patients with postoperative intermediate- and high-risk LA-HNSCC. METHODS: We retrospectively reviewed 47 postoperative intermediate- and high-risk patients with LA-HNSCC who underwent operative interventions between 2016 and 2022. These patients were divided into two groups: a standard therapy group (n = 24) and an adjuvant immunotherapy group (n = 23 standard therapy + immunotherapy). The primary endpoint was 2-year progression-free survival (PFS) and 2-year overall survival (OS). Stratification analysis according to baseline combined positivity score (CPS), with cutoffs set at CPS ≥ 20, was performed to analyze the correlation between CPS and treatment outcomes. RESULTS: The 2-year PFS and OS rates in the adjuvant immunotherapy group were 82.6% and 96.0%, respectively, compared to 62.5% (χ2 = 2.376, P = 0.123) and 75.0% (χ2 = 3.646, P = 0.056) in the standard therapy group. Stratified analysis showed that the 2-year PFS and OS rates for patients in the adjuvant immunotherapy group with programmed death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 significantly improved compared to the standard therapy group (93.3% vs. 62.5%, χ2 = 4.573, P = 0.033), (100.0% vs. 75.0%, χ2 = 4.212, P = 0.040). CONCLUSION: This cohort study found that adjuvant immunotherapy after the standard of care improved PFS and OS in patients with postoperative intermediate- and high-risk LA-HNSCC, especially for those with a PD-L1 CPS of 20 or more.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Changhai Hospital, Naval Medical University, No. 168, Changhai Road, Yangpu District, Shanghai, China.
- Department of Otolaryngology, Eastern Hepatic Surgery Hospital, Naval Medical University, Shanghai, China.
- Department of Otolaryngology, Changhai Hospital, Naval Medical University, No. 168, Changhai Road, Yangpu District, Shanghai, China. fshzhang2002@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Shi, X., Zhu, M., He, J., Gao, Y., Ma, Y., Li, H., Yu, G., Zhao, L., Zheng, H., & Zhang, C. (2025). Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study. European Archives of Oto-Rhino-Laryngology, 282(10), 5333-5341. https://doi.org/10.1007/s00405-025-09602-7
Vancouver
Shi X, Zhu M, He J, Gao Y, Ma Y, Li H, et al. Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study. European Archives of Oto-Rhino-Laryngology. 2025;282(10):5333-5341. doi:10.1007/s00405-025-09602-7
BibTeX
@article{Shi2025,
author = {Shi, Xiaoqiong and Zhu, Minhui and He, Jianqiao and Gao, Yingna and Ma, Yi and Li, Haopu and Yu, Guoning and Zhao, Lin and Zheng, Hongliang and Zhang, Caiyun},
title = {Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2025},
volume = {282},
number = {10},
pages = {5333--5341},
doi = {10.1007/s00405-025-09602-7}
}
EUVIMED